

CARIDIANBCT AND TERUMO TRANSFUSION ARE BECOMING



MEDIA ADVISORY

Contact:

Laura Fusco
Global Corporate Communications
Phone: +1 303.205.2546
press@caridianbct.com

David Perez to Testify before U.S. House Energy and Commerce Health Subcommittee *Hearing Scheduled to Discuss Reauthorization of the Medical Device User Fee Act*

Lakewood, Colo. —February 15, 2012—David Perez, president and chief executive officer of Terumo BCT and Chairman of Terumo Corporation’s Blood Management Business Board, will testify on February 15, 2012 before the U.S. House Committee on Energy and Commerce Health Subcommittee. Perez will provide testimony in the discussion about the reauthorization of the Medical Device User Fee Act (MDUFA).

As the leading global provider of innovative technologies, products and services in the areas of: blood collection, processing, safety, clinical procedures, cell culture and cell therapies, Terumo BCT is providing testimony on behalf of the medical device industry that emphasizes the importance of working in partnership with the Food and Drug Administration to implement process improvements that have the potential to improve the lives of patients.

EVENT DETAILS:

WHAT: David Perez delivering Congressional Testimony

WHERE: Rayburn House Office Building
Room 2322
Washington, DC

WATCH: To Watch This Testimony Live visit:

WHEN: February 15, 2012

TIME: 10:00 a.m. (EST)

WHY: To discuss the reauthorization of MDUFA—What it means for jobs, innovation and patients

WHO: David Perez, President and CEO of Terumo BCT and
Chairman of Terumo Corporation’s Blood Management Business Board

ABOUT DAVID PEREZ:

David Perez is president and chief executive officer of the combined businesses of CaridianBCT and Terumo Transfusion—Terumo BCT—and serves as Chairman of Terumo Corporation's Blood Management Business board. Terumo BCT is the leading global provider of innovative technologies and services specializing in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies. Perez is responsible for leading the strategic direction, growth and execution of this combined global organization with revenues in excess of \$875 million.

A dedicated and active industry leader with nearly 30 years of experience within the medical device and health care industries, Perez also lends his expertise to numerous boards and councils. He serves the Advanced Medical Technology Association (AdvaMed) on the board of directors and on the Executive Committee, chairing both the Technology and Regulatory Affairs Committee and the Blood Products and Technology Sector. Perez is also chair of the board of trustees for the National Blood Foundation (NBF); a member of the NBF Council on Research and Development; and a board member of the Foundation for America's Blood Centers®, the Colorado BioScience Association and the Fitzsimons Redevelopment Authority for the Colorado life sciences community.

Perez has been with the organization for more than 13 years. Previously he held leadership positions at Uro Therapies Inc., Haemonetics® Corp., Caremark LLC, Coram Healthcare Corp. and Kendall. He earned his bachelor's degree in political science from Texas Tech University.

ABOUT THE MEDICAL DEVICE USER FEE ACT (MDUFA):

The medical device user fee program, originally enacted in the Medical Device User Fee and Modernization Act (MDUFMA), and renewed in the Medical Device User Fee Amendments of 2007 (MDUFA). The legislative authority for the medical device user fee program expires in September 2012. At that time, new legislation will be required for FDA to continue collecting user fees for the medical device program. The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that before FDA begins negotiations with the regulated industry on medical device user fee program reauthorization, we hold a public meeting at which the public may present its views on the reauthorization and provide a period of 30 days after the public meeting to obtain written comments from the public suggesting changes.

ABOUT TERUMO BCT:

CaridianBCT and Terumo Transfusion are becoming Terumo BCT, the world leader in blood component technology. Together, we believe in the potential of blood to do even more for the world than it does today. This belief unites our organization, inspires our innovation and strengthens our collaboration with customers to ultimately benefit the patients we all serve. The transition to Terumo BCT will be complete in April 2012.